{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:53:24Z","timestamp":1768002804571,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T00:00:00Z","timestamp":1366156800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00277-013-1746-9","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T05:56:26Z","timestamp":1366091786000},"page":"1249-1254","source":"Crossref","is-referenced-by-count":35,"title":["Bendamustine salvage therapy for T cell neoplasms"],"prefix":"10.1007","volume":"92","author":[{"given":"Francesco","family":"Zaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s J. M.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Goldaniga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Volpetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,17]]},"reference":[{"issue":"11","key":"1746_CR1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"The Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","unstructured":"The Non-Hodgkin\u2019s Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. Blood 89(11):3909\u20133918","journal-title":"Blood"},{"issue":"3","key":"1746_CR2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","volume":"26","author":"A Dodero","year":"2012","unstructured":"Dodero A, Spina F, Narni F et al (2012) Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 26(3):520\u2013526","journal-title":"Leukemia"},{"issue":"7","key":"1746_CR3","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/annonc\/mdr140","volume":"22","author":"C Hosing","year":"2011","unstructured":"Hosing C, Champlin RE (2011) Stem-cell transplantation in T cell non-Hodgkin\u2019s lymphomas. Ann Oncol 22(7):1471\u20131477","journal-title":"Ann Oncol"},{"issue":"1","key":"1746_CR4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.12000","volume":"159","author":"WU Knauf","year":"2012","unstructured":"Knauf WU, Lissitchkov T, Aldaoud A et al (2012) Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol 159(1):67\u201377. doi: 10.1111\/bjh.12000 , Epub 2012 Aug 4","journal-title":"Br J Haematol"},{"issue":"26","key":"1746_CR5","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","volume":"29","author":"K Fischer","year":"2011","unstructured":"Fischer K, Cramer P, Busch R et al (2011) Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29(26):3559\u20133566","journal-title":"J Clin Oncol"},{"issue":"26","key":"1746_CR6","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","volume":"30","author":"K Fischer","year":"2012","unstructured":"Fischer K, Cramer P, Busch R et al (2012) Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase ii trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 30(26):3209\u20133216. doi: 10.1200\/JCO.2011.39.2688 , Epub 2012 Aug 6","journal-title":"J Clin Oncol"},{"issue":"15","key":"1746_CR7","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ et al (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol 23(15):3383\u20133389","journal-title":"J Clin Oncol"},{"issue":"27","key":"1746_CR8","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH et al (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B cell and mantle cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 26(27):4473\u20134479","journal-title":"J Clin Oncol"},{"issue":"9","key":"1746_CR9","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/j.1349-7006.2010.01635.x","volume":"101","author":"K Ohmachi","year":"2010","unstructured":"Ohmachi K, Ando K, Ogura M et al (2010) Multicenter phase II study of bendamustine for relapsed or refractory indolent B cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101(9):2059\u20132064","journal-title":"Cancer Sci"},{"issue":"1","key":"1746_CR10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","volume":"116","author":"BS Kahl","year":"2010","unstructured":"Kahl BS, Bartlett NL, Leonard JP et al (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 116(1):106\u2013114","journal-title":"Cancer"},{"issue":"1","key":"1746_CR11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","volume":"31","author":"G Damaj","year":"2013","unstructured":"Damaj G, Gressin R, Bouabdallah K et al (2013) Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T cell lymphomas: the BENTLY trial. J Clin Oncol 31(1):104\u201310. doi: 10.1200\/JCO.2012.43.7285 , Epub 2012 Oct 29","journal-title":"J Clin Oncol"},{"issue":"5","key":"1746_CR12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"issue":"18","key":"1746_CR13","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"EA Olsen","year":"2011","unstructured":"Olsen EA, Whittaker S, Kim YH et al (2011) Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 29(18):2598\u20132607","journal-title":"J Clin Oncol"},{"issue":"18","key":"1746_CR14","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30(18):2190\u20132196","journal-title":"J Clin Oncol"},{"issue":"9","key":"1746_CR15","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L et al (2011) Pralatrexate in patients with relapsed or refractory peripheral T cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29(9):1182\u20131189","journal-title":"J Clin Oncol"},{"issue":"32","key":"1746_CR16","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","volume":"27","author":"RL Piekarz","year":"2009","unstructured":"Piekarz RL, Frye R, Turner M et al (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T cell lymphoma. J Clin Oncol 27(32):5410\u20135417","journal-title":"J Clin Oncol"},{"issue":"22","key":"1746_CR17","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"Piekarz RL, Frye R, Prince HM et al (2011) Phase 2 trial of romidepsin in patients with peripheral T cell lymphoma. Blood 117(22):5827\u20135834","journal-title":"Blood"},{"issue":"6","key":"1746_CR18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM et al (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T cell lymphoma after prior systemic therapy. J Clin Oncol 30(6):631\u2013636","journal-title":"J Clin Oncol"},{"key":"1746_CR19","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","volume":"116","author":"G Dueck","year":"2010","unstructured":"Dueck G, Chua N, Prasad A et al (2010) Interim report of a phase 2 clinical trial of lenalidomide for T cell non-Hodgkin lymphoma. Cancer 116:4541\u20134548","journal-title":"Cancer"},{"issue":"46","key":"1746_CR20","doi-asserted-by":"crossref","first-page":"Abs95","DOI":"10.1182\/blood.V118.21.95.95","volume":"118","author":"J Friedberg","year":"2011","unstructured":"Friedberg J, Mahadevan D, Jung JA et al (2011) Phase 2 trial of Alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B an T cell non-Hodgkin lymphoma (NHL) [Abstract]. Blood 118(46):Abs95","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1746-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-013-1746-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1746-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T23:34:16Z","timestamp":1715211256000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-013-1746-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,17]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["1746"],"URL":"https:\/\/doi.org\/10.1007\/s00277-013-1746-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,17]]}}}